Drug hypersensitivity reactions (DHRs) are common, and the skin is by far the most frequently involved organ with a broad spectrum of reaction types. The diagnosis of cutaneous DHRs (CDHR) may be difficult because of multiple differential diagnoses.
easily lead to the wrong conclusion regarding diagnosis and management. This guideline focuses on the clinical manifestations of DHR which aid correct diagnostic classification. As recommended by the international consensus on drug allergy, we use the term DHR for objectively reproducible symptoms or signs initiated by exposure to a defined drug at a dose tolerated by a normal person that clinically resembles allergy, and we are focusing on cutaneous DHR (CDHR). 1 Other terms used for CDHR nomenclature are explained in Table S1 .
The guideline aims to assist all clinicians managing DHR by providing the approach needed for doctors to correctly classify CDHR.
Importantly, we have included precise definitions of CDHR, which we hope can become a standard tool for reference. Included in this guideline are criteria for when to think of DHR; an overview and a classification of CDHR; a detailed clinical description of morphological aspects in the skin; differences between urticaria and exanthems; differential diagnoses; how to distinguish between different forms of CDHR; danger signs; and important considerations for diagnosis and management.
Another part of the guideline is aimed at patients to give a standardized and better description of their skin manifestations as well as for important information to be given to the patient by the physician. Finally, recommendations for audit points are included. Table S1 . We restricted the content of this article to CDHR after systemic exposure. During the development of these guidelines, the consultation process included meetings in 
| MATERIAL AND METHODS

| DESCRIPTION OF CUTANEOUS DH RS
| How to classify cutaneous DHRs
Correct classification of CDHR into well-defined entities strongly depends on a thorough clinical examination and correct description of morphological features of the skin. As skin lesions constitute the essential foundation for later diagnosis, they are explained and summarized in Figure S1 and Table S2 . Furthermore, dermatological terms used for the morphological description are given in Table S3 .
Drug hypersensitivity reactions have also been classified according to chronology. Immediate (acute) DHRs are correspondent to urticaria, angioedema and/or anaphylaxis occurring nearly always within the first hour, and nonimmediate (late) exanthems occur later than 6 hours, mostly 24 hours, after drug intake. Whilst morphological classification from characterization of primary lesions and clinical features remains most important, sometimes chronology gives further clues to the diagnosis, or aids exclusion of CDHR, or differentiation between CDHR. For example, chronology is very helpful to distinguish between urticaria and early MPEs (Table 1) . It is important to recognize that, post hoc, history of reported chronology is potentially unreliable, because it depends on the information provided by the patient. Morphology is more reliable, if it is assessed by experienced physicians in the acute phase, but needs to be described and classified correctly. Disease extent can be described as generalized (widespread; no major regions of skin are exempt), disseminated (several skin regions are involved) or localized (limited to a certain area of the body). (Figures 1 and 2) . 5 Wheals can be localized anywhere on the body. Urticaria has a fleeting nature, with the skin returning to its normal appearance, usually within 24 hour, 5 but the continual appearance and disappearance of new lesions is characteristic. 6 When oedema in the skin is larger and involves the deeper dermis ± subcutis, the condition is called angioedema. Angioedema often affects the face (cheeks, eyelids, lips or ears) and genitalia, but also buccal mucosa, tongue, larynx and pharynx. It is often accompanied by pain and heat rather than itching. Its resolution is slower than that of wheals and may last for several days. 7 Urticaria and angioedema are associated in about half of cases.
Urticaria and angioedema can be accompanied by systemic involvement (normally cardiovascular or respiratory involvement), which has been defined as anaphylaxis 8 and can lead to respiratory collapse, shock and death. 9 Anaphylaxis mostly comes with skin lesions such as urticaria or a generalized flush, but rarely may occur without either. Drug-related urticaria, angioedema or anaphylaxis usually begins within 1 hour of drug administration. However, angioedema alone (without urticaria) induced as a side effect of angiotensinconverting enzyme inhibitors may begin after months or years of treatment, although this is not a true "hypersensitivity" reaction.
| Disseminated and generalized exanthems
An exanthem is not a disease, but a description of a clinical picture.
There is no consensus definition of an exanthem. Medical dictionaries define it either as any rash, as a widespread rash, or as a rapidly erupting rash that may have diagnostic features of an infectious disease. In Greek, exanthema (ἐξάνθημα exánthēma) stands for "blossoming" or "breaking out" highlighting the sudden appearance and colour change in the eruption. We define an exanthem as an acutely Bullous lesions develop fast, often within 12 hours, both on the skin and on mucous membranes (oral, nasal, conjunctival, genital, anal).
Suspicion of cutaneous drug hypersensitivity reaction Differential diagnoses considered (see chapter on differential diagnosis, Table S5) Drug exposure timeline compatible (see Table 1 ) Clinical picture compatible (see Table 2 ) Consider other diagnoses such as allergic contact dermatitis, contact urticaria (see chapter on differential diagnoses)
Disseminated or generalized
F I G U R E 1 Algorithm for cutaneous drug hypersensitivity reaction. *This is a suggestive algorithm focusing on the most important entities of systemic effects of drugs and not exhaustive in diagnostic procedures recommended. **For criteria for anaphylaxis see Muraro A, et al. Allergy 2014; 69: 1026-1045. ***Pure drug induced vasculitis is rare and may complicate other hypersensitivity reactions. ****Single/minimal vesicles, pustules, purpura or eczema may in selected cases occur in maculopapular exanthem or drug reaction with eosinophilia and systemic symptoms (DRESS) and may not justify classification in above entities age of the patient and extent of skin detachment. 12 Furthermore, the time to withdrawal of the culprit drug is important prognostically. 13 The typical time latency between first dose of drug and patients with GBFDE have no systemic symptoms, the lesions are well demarcated, and the mucous membranes are rarely or only minimally involved. In contrast to SJS/TEN, the culprit drug has usually been taken and tolerated before (sensitization period) and milder earlier episodes are often reported. However, recurrent events may increase in severity leading to a substantial death rate in elderly patients (up to 22%). 
Vasculitis
Vasculitis is frequently suspected and seldom confirmed to be caused by drug ingestion. 17, 18 The most common type, drug-induced leukocytoclastic vasculitis, presents with palpable purpura, petechiae, bullae which can lead to necrosis and is indistinguishable from vasculitis due to other causes. When accompanied by fever, arthralgia, haematuria or proteinuria as well as lymphadenopathy, a serum sickness reaction can be suspected. Serum-sickness-like reactions have been particularly described in children after intake of cefaclor.
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Drug reaction with eosinophilia and systemic symptoms
Drug reaction with eosinophilia and systemic symptoms is a severe condition that often starts with MPE also involving internal organs. Mortality has been variably reported, usually related to liver failure, but in a large series of strictly validated cases of DRESS was 2%. 20 However, prolonged courses and flare-ups, even after discontinuation of the culprit drug, are common. 
Maculopapular exanthem
The most frequent DHRs are MPE. 21, 22 MPEs usually appear between four and 14 days after a new drug has been started. However, in a 
Distinguishing MPE from other disseminated and generalized exanthems
It is important to note that MPE is essentially diagnosed by exclusion.
Although the patient with MPE may develop fever, mild systemic symptoms, or rarely minimal vesicles or pustules, they do not show the typical features of one of the specific severe entities (as described above). Therefore, the course of the MPE has to be regularly monitored in the initial phase to exclude early signs of DRESS, SJS/TEN or AGEP. A diagnosis of MPE is retained because of the benign course and clinical picture.
There are cases, which show features of two different of the described entities, for example DRESS and SJS/TEN, AGEP and SJS/TEN or AGEP and SDRIFE, or any of these and MPE. We do not encourage the routine use of the term "overlap" and it is recommended to use one diagnosis based on the most important clinical features, although this may be difficult in some patients. predominantly affecting the sun-exposed areas (may also spread to covered body sites), whereas phototoxic reactions cause sunburn-like changes (sharply demarcated erythema, with or without vesicles and blisters, and subsequent hyperpigmentation). The onset of photoallergy after drug exposure varies from a few days to 3 years of daily drug intake. [23] [24] [25] [26] Such variability may be due to the fact that the development of photoallergy is also dependent upon the highly unpredictable exposure of individuals to provoking light. Differentiating photoallergic and phototoxic reactions can difficult and will often require specialist assessment. In the case of photoallergic reactions, borders of involved areas are typically less well demarcated, with erythema, oedema and papules often spreading to covered skin areas.
| Systemic photoallergic reactions
The eruption often demonstrates an aggravating "crescendo" pattern lasting for a few days after discontinuation of exposures, whereas phototoxic reactions usually subside immediately after withdrawal of either provoking factor (drug, light). 24 Photopatch testing with suspected drugs is essential for diagnosis. of an urticaria. It is recommended to circle around one or several lesions of a patient with a pen and check the persistence of these outlines for differentiation after 1 and 2 days. Chronological information, monitoring the course of the disease and duration of wheals (±histology rarely), may be needed to make the distinction.
Exanthems may be morphologically subdivided according to their dominant primary skin lesions, shape or resemblance of other diseases into maculopapular, lichenoid (resembling lichen planus), urticarial (resembling urticaria, but longer lasting lesions), morbilliform (measles-like), vesicular (with vesicles), pustular (with pustules), acneiform (resembling acne vulgaris) exanthem (Table S4) . We are summarizing all these forms under the diagnosis MPE to avoid confusion in nomenclature and because the predominant picture may change with time as well as not be consistent in all skin areas. with a skin eruption, followed by eosinophilia after several days (occasionally more than 1 week later), and by liver involvement another week later. Therefore, repeated laboratory tests are needed to confirm or exclude DRESS, especially when an extensive skin eruption with constitutional symptoms is present.
| Danger signs
37,38
| Differential diagnosis
There are multiple differential diagnoses for CDHR. The most important differential diagnosis of a drug-induced exanthem is an exanthem caused by an infection. 39, 40 On a population level, the most common cause of an exanthem is a viral infection, particularly in children. 41 Traditionally, six classic infectious exanthems have been described, that is measles (measles virus infection), scarlet fever (group A streptococcus infection), rubella (rubella virus infection), erythema infectiosum (syn. slapped cheek/fifth disease; parvovirus B19 infection), and exanthema subitum (syn. Roseola infantum; HHV-6 infection). Duke disease, syn. fourth disease, is no longer considered a specific entity. These exanthems are characterized by pathognomonic features ( in a nonimmunological manner. [44] [45] [46] In a person with genetic background for psoriasis, a drug-induced exanthem may induce psoriasis. T A B L E 3 Drug hypersensitivity questionnaire (shortened from 47)
In eczema, the clinical presentation of lesions is more diffuse and shows primary scaling reflecting epidermal inflammation (as compared to disseminated smaller lesions without scaling in the first days of MPE). Erythroderma (Table S3 ) may also be induced by drugs, but more commonly erythroderma is induced by atopic dermatitis, psoriasis, pityriasis rubra pilaris and cutaneous lymphoma.
Pityriasis rosea is a, sometimes pruritic, self-limited eruption mainly in adolescents and young adults. In this disease, a primary welldemarcated plaque on the trunk is followed by eruption of numerous smaller plaques with central fine scales often in a "Christmas tree"
pattern. Other dermatological diseases that may mimic drug exanthems include systemic lupus erythematosus and dermatomyositis, and in cases with blisters, autoimmune blistering skin diseases, such as bullous pemphigoid or IgA-linear dermatosis. Kawasaki disease, unilateral laterothoracic exanthem and Schönlein-Henoch purpura are primarily differential diagnoses to CDHR in children.
| CONCLUSIONS AND FUTURE NEEDS
The diagnosis of CDHR may be difficult because of multiple differential diagnoses, particularly acute spontaneous urticaria and infectious exanthems, but also other dermatological diseases. To suspect a CDHR:
1. A new drug (or repeated intake of a drug) has to be introduced to the patient with a specific time interval between intake and development of first symptoms (Table 1 ) and
2. Typical clinical manifestations should be present (Table 2 ). These features differ substantially between the various clinical conditions. To make the correct diagnosis based on morphology, it is crucial to identify primary and secondary lesions (Table S2) and to use allergological (Table S1 ) and dermatological terms appropriately (Table S3) .
Most cases are elicited by classical culprit drugs (Table 1) . However, this CDHR must be considered due to nonclassical drugs if Often, information regarding the clinical reaction is only available from the patient or caregiver, in some cases with medical records (eg discharge letter, medical chart, anaesthesia protocols). In these cases, photography of the clinical reaction by the patient (often with smartphones) to identify the lesion pattern and body distribution is very helpful and should be asked for. Appendix S1 describes a questionnaire for the patient to identify the principal information about the reaction. However, it is important to recognize that the information given by the patient is prone to error with significant limitations because of the lack of medical training. To monitor internal standards of these recommendations, audit points are given (Table S6) .
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